The results are important for the potential application of TRAIL as a treatment for colorectal cancer because of the current focus on the mechanisms of TRAIL resistance in colorectal tumours – it will be important to define the ‘window’ of TRAIL sensitivity. The gene discussed is TNFSF10; the disease is colorectal neoplasm.